Peptide-drug Conjugate Information
General Information of This Peptide-drug Conjugate (PDC)
| PDC ID |
PDC_00067
|
|||||
|---|---|---|---|---|---|---|
| PDC Name |
BP9a-SS-DOX
|
|||||
| PDC Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Tumor
|
|||||
| Structure |
|
|||||
| Peptide Name |
BP9a
|
Peptide Info | ||||
| Receptor Name |
Transferrin receptor protein 1 (TFRC)
|
Receptor Info | ||||
| Drug Name |
Doxorubicin
|
Drug Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Disulfide bond
|
Linker Info | ||||
| Peptide Modified Type |
Amino acid modifications
|
|||||
| Modified Segment |
Cysteine
|
|||||
| Ternimal Modification |
N-terminal modification
|
|||||
| Formula |
C67H91N17O23S2
|
|||||
| #Ro5 Violations (Lipinski): 5 | Molecular Weight | 1566.695 | ||||
| Lipid-water partition coefficient (xlogp) | -5.3453 | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 21 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 28 | |||||
| Rotatable Bond Count (rotbonds) | 42 | |||||
Full List of Activity Data of This Peptide-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Tumor | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
6.21 ± 1.12 µM
|
|||
| Evaluation Method | CCK-8 assay | ||||
| Description |
The BP9a-SS-DOX conjugate exhibited impressed antiproliferative activity against HepG2 cells with an IC50 value of 6.21 ± 1.12 uM which was lower than that of free DOX.
|
||||
| In Vitro Model | Hepatoblastoma | Hep-G2 cell | CVCL_0027 | ||
References